W. Cameron Black
Research Subjects
W. Cameron Black has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
M. David Percival
Departments of Medicinal Chemistry and Biochemistry Molecular Biology and Pharmacology Merck Frosst Centre for Therapeutic Research P. O. Box 1005, Pointe‐Claire‐Dorval, Québec, H9R 4P8, Canada, Fax: (+1) 514‐428‐4900
2 shared publicationsAndré Giroux
Merck Frosst Centre for Therapeutic Research, Merck Frosst Canada & Co., PO Box 1005, Pointe-Claire-Dorval, Que., Canada H9R 4P8
1 shared publicationChi-Chung Chan
1 shared publicationChristine Brideau
1 shared publication- Christophe Mellon
Merck Frosst Centre for Therapeutic Research, Merck Frosst Canada & Co., PO Box 1005, Pointe-Claire-Dorval, Que., Canada H9R 4P8
1 shared publication Christopher I. Bayly
1 shared publication
Latest Publications
- 1 May 2010
- Published by Bentham Science Publishers Ltd. in Current Topics in Medicinal Chemistry
- Vol. 10 (7) , 745-751
Peptidomimetic Inhibitors of Cathepsin K
Cathepsin K (Cat K) is the primary enzyme involved in Type I collagen degradation in bone resorption. The development of a Cat K inhibitor should provide an effective treatment for osteoporosis. Key components of a clinically viable inhibitor are oral bioavailability, high selectivity over related cathepsins, and a covalent, reversible warhead to bind to the active site cysteine of the enzyme. This article reviews recent advances in the design of inhibitors derived from peptidic leads that contain either a ketone or nitrile electrophile. Three of these compounds have progressed into clinical trials and one, odanacatib (5), is currently in Phase III studies for the treatment of post-menopausal osteoporosis.
- 1 May 2010
- Published by Bentham Science Publishers Ltd. in Current Topics in Medicinal Chemistry
- Vol. 10 (7) , 745-751
Peptidomimetic Inhibitors of Cathepsin K
Cathepsin K (Cat K) is the primary enzyme involved in Type I collagen degradation in bone resorption. The development of a Cat K inhibitor should provide an effective treatment for osteoporosis. Key components of a clinically viable inhibitor are oral bioavailability, high selectivity over related cathepsins, and a covalent, reversible warhead to bind to the active site cysteine of the enzyme. This article reviews recent advances in the design of inhibitors derived from peptidic leads that contain either a ketone or nitrile electrophile. Three of these compounds have progressed into clinical trials and one, odanacatib (5), is currently in Phase III studies for the treatment of post-menopausal osteoporosis.
- 15 March 2007
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 17 (6) , 1671-1674
Solid-phase analogue synthesis of caspase-3 inhibitors via palladium-catalyzed amination of 3-bromopyrazinones
- 15 March 2007
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 17 (6) , 1671-1674
Solid-phase analogue synthesis of caspase-3 inhibitors via palladium-catalyzed amination of 3-bromopyrazinones
- 29 September 2006
- Published by Wiley in ChemBioChem
- Vol. 7 (10) , 1525-1535
The Consequences of Lysosomotropism on the Design of Selective Cathepsin K Inhibitors
Many drug candidates contain a basic functional group that results in lysosomotropism—the accumulation of drug in the acidic lysosomes of a cell. When evaluating inhibitors of lysosomal enzymes, such as the cathepsins, this physical property can have a dramatic impact on the functional selectivity of the test compounds. A basic P3 substituent in cathepsin K inhibitors provides a means of achieving potent and selective enzyme inhibition. To evaluate the whole‐cell selectivity of the basic cathepsin K inhibitor L‐006235, we identified the irreversible pan‐selective cathepsin probe BIL‐DMK and used it to design whole‐cell enzyme‐occupancy assays. These cell‐based assays showed a dramatic reduction in selectivity against cathepsins B, L, and S relative to the selectivities observed in enzyme assays. Two‐photon confocal fluorescence microscopy showed punctated subcellular localization of L‐006235, which colocalized with BODIPY‐labelled Lysotracker, consistent with compound lysosomotropism. To address this potential problem, a series of potent cathepsin K inhibitors was developed by replacing the P2P3 amide bond with a metabolically stable trifluoroethylamine moiety. X‐ray crystallography has identified the binding of this functional group to active‐site residues in cathepsin K. This modification resulted in increased potency and selectivity that allowed the removal of the basic P3 substituent. The resulting nonbasic inhibitor L‐873724 is a 0.2 nMinhibitor of cathepsin K with cathepsin B, L, and S potencies that were not shifted between purified enzyme and whole‐cell assays; thus indicating that this compound is not lysosomotropic. L‐873724 exhibits excellent pharmacokinetics and is orally active in a monkey model of osteoporosis at 3 mg kg−1q.d.
- 29 September 2006
- Published by Wiley in ChemBioChem
- Vol. 7 (10) , 1525-1535
The Consequences of Lysosomotropism on the Design of Selective Cathepsin K Inhibitors
Many drug candidates contain a basic functional group that results in lysosomotropism—the accumulation of drug in the acidic lysosomes of a cell. When evaluating inhibitors of lysosomal enzymes, such as the cathepsins, this physical property can have a dramatic impact on the functional selectivity of the test compounds. A basic P3 substituent in cathepsin K inhibitors provides a means of achieving potent and selective enzyme inhibition. To evaluate the whole‐cell selectivity of the basic cathepsin K inhibitor L‐006235, we identified the irreversible pan‐selective cathepsin probe BIL‐DMK and used it to design whole‐cell enzyme‐occupancy assays. These cell‐based assays showed a dramatic reduction in selectivity against cathepsins B, L, and S relative to the selectivities observed in enzyme assays. Two‐photon confocal fluorescence microscopy showed punctated subcellular localization of L‐006235, which colocalized with BODIPY‐labelled Lysotracker, consistent with compound lysosomotropism. To address this potential problem, a series of potent cathepsin K inhibitors was developed by replacing the P2P3 amide bond with a metabolically stable trifluoroethylamine moiety. X‐ray crystallography has identified the binding of this functional group to active‐site residues in cathepsin K. This modification resulted in increased potency and selectivity that allowed the removal of the basic P3 substituent. The resulting nonbasic inhibitor L‐873724 is a 0.2 nMinhibitor of cathepsin K with cathepsin B, L, and S potencies that were not shifted between purified enzyme and whole‐cell assays; thus indicating that this compound is not lysosomotropic. L‐873724 exhibits excellent pharmacokinetics and is orally active in a monkey model of osteoporosis at 3 mg kg−1q.d.
- 1 November 2005
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 15 (21) , 4741-4744
Trifluoroethylamines as amide isosteres in inhibitors of cathepsin K
- 1 November 2005
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 15 (21) , 4741-4744
Trifluoroethylamines as amide isosteres in inhibitors of cathepsin K
- 1 March 2003
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 13 (6) , 1195-1198
3,4-Diaryl-5-hydroxyfuranones: highly selective inhibitors of cyclooxygenase-2 with aqueous solubility
- 1 March 2003
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 13 (6) , 1195-1198
3,4-Diaryl-5-hydroxyfuranones: highly selective inhibitors of cyclooxygenase-2 with aqueous solubility
- 1 August 1998
- Published by Georg Thieme Verlag KG in Synthesis
- Vol. 1998 (08) , 1101-1103
Synthesis of Sulfonyl Flosulide
- 1 August 1998
- Published by Georg Thieme Verlag KG in Synthesis
- Vol. 1998 (08) , 1101-1103
Synthesis of Sulfonyl Flosulide